Organovo Holdings, Inc. (ONVO), a clinical-stage biotech firm focused on advancing innovative treatments for inflammatory bowel ...

Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today ...

StockNews.com initiated coverage on shares of Organovo (NASDAQ:ONVO – Free Report) in a research note issued to investors on Sunday morning. The brokerage issued a sell rating on the medical research ...

Organovo Holdings, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Organovo Holdings Inc. (ONVO) on Friday reported a loss of $2.5 million in its fiscal second quarter. The San Diego-based company said it had a loss of 14 ...

SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel ...

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply ...

Short interest in Organovo Holdings Inc (NASDAQ:ONVO) increased during the last reporting period, rising from 32.50K to 39.07K. This put 0.26% of the company's publicly available shares short.

Find the latest Organovo Holdings, Inc. ONVO analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.

Organovo stock opened at $0.41 on Friday. Organovo has a 12-month low of $0.32 and a 12-month high of $1.74. The stock has a 50-day simple moving average of $0.43 and a 200 day simple moving ...

Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...